These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29522648)

  • 1. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
    Golding JF; Wesnes KA; Leaker BR
    Br J Clin Pharmacol; 2018 Jul; 84(7):1535-1543. PubMed ID: 29522648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
    Kay GG; Wesnes KA
    BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
    Hill S; Khullar V; Wyndaele JJ; Lheritier K;
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
    Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
    BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.
    Zinner N; Tuttle J; Marks L
    World J Urol; 2005 Sep; 23(4):248-52. PubMed ID: 16096831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of cognitive function of the elderly population: effects of darifenacin.
    Lipton RB; Kolodner K; Wesnes K
    J Urol; 2005 Feb; 173(2):493-8. PubMed ID: 15643227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
    Gratzke C
    Eur Urol; 2007 Sep; 52(3):848. PubMed ID: 17360107
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
    Reitz A
    Eur Urol; 2007 Sep; 52(3):848-9. PubMed ID: 17360105
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
    Foote J; Glavind K; Kralidis G; Wyndaele JJ
    Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
    Iijima K; De Wachter S; Wyndaele JJ
    Eur Urol; 2007 Sep; 52(3):842-7. PubMed ID: 17360104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scopolamine (hyoscine) for preventing and treating motion sickness.
    Spinks A; Wasiak J
    Cochrane Database Syst Rev; 2011 Jun; 2011(6):CD002851. PubMed ID: 21678338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.
    Kay GG; Ebinger U
    Int J Clin Pract; 2008 Nov; 62(11):1792-800. PubMed ID: 18699842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal Scopolamine for Motion Sickness.
    Stankovic AS; Alvarenga DL; Coleman Daniels VR; Simmons RG; Buckey JC; Putcha L
    Aerosp Med Hum Perform; 2019 Nov; 90(11):917-924. PubMed ID: 31666152
    [No Abstract]   [Full Text] [Related]  

  • 15. Scopolamine (hyoscine) for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2007 Jul; (3):CD002851. PubMed ID: 17636710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased warning time with darifenacin: a new concept in the management of urinary urgency.
    Cardozo L; Dixon A
    J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.
    Yamada S; Maruyama S; Takagi Y; Uchida S; Oki T
    Life Sci; 2006 Dec; 80(2):127-32. PubMed ID: 16996089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
    Haab F; Stewart L; Dwyer P
    Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans.
    Bharucha AE; Ravi K; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2010 Jul; 299(1):G215-9. PubMed ID: 20395537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
    Yoshida A; Maruyama S; Fukumoto D; Tsukada H; Ito Y; Yamada S
    Life Sci; 2010 Jul; 87(5-6):175-80. PubMed ID: 20598326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.